0 626

Cited 14 times in

Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes

DC Field Value Language
dc.contributor.author김수정-
dc.contributor.author김윤덕-
dc.contributor.author정준원-
dc.date.accessioned2015-12-28T11:04:36Z-
dc.date.available2015-12-28T11:04:36Z-
dc.date.issued2014-
dc.identifier.issn0925-5710-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/138641-
dc.description.abstractAllogeneic hematopoietic stem cell transplantation (alloSCT) is currently the only curative treatment modality for myelodysplastic syndromes (MDS). The treatment paradigm for MDS has changed in recent years with the introduction of hypomethylating agents (HMAs). The present retrospective multicenter study was designed to assess the effects of pre-transplant HMA on transplant outcome and determine which patients would benefit most from this therapy. A total of 109 patients who received alloSCT at one of five institutions between 2007 and 2010 were enrolled in this study regardless of pre-transplant HMA therapy. 81 of the 109 patients enrolled were treated with HMA prior to alloSCT. 28 patients received alloSCT without HMA bridging. The distributions of WHO classification groups and IPSS scores were similar between the two groups (P = 0.752 and P = 0.265, respectively). Pre-transplant HMA did not affect OS (P = 0.244), and there were no differences in response to HMA therapy within the HMA-treated group. The cumulative incidence of NRM was not significantly different between the two groups (P = 0.500). However, for patients with a high blast count (>5 % of bone marrow at the time of diagnosis), pre-transplant HMA therapy had a NRM benefit (83.3 vs. 48.6 %, P = 0.014).-
dc.description.statementOfResponsibilityopen-
dc.format.extent635~643-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF HEMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntimetabolites, Antineoplastic/therapeutic use*-
dc.subject.MESHAzacitidine/therapeutic use*-
dc.subject.MESHDNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors*-
dc.subject.MESHFemale-
dc.subject.MESHHematopoietic Stem Cell Transplantation-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMyelodysplastic Syndromes/diagnosis-
dc.subject.MESHMyelodysplastic Syndromes/drug therapy*-
dc.subject.MESHMyelodysplastic Syndromes/mortality-
dc.subject.MESHMyelodysplastic Syndromes/therapy-
dc.subject.MESHPreoperative Care-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTransplantation, Homologous-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titleMulticenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorYundeok Kim-
dc.contributor.googleauthorIn Ho Kim-
dc.contributor.googleauthorHyeong Joon Kim-
dc.contributor.googleauthorSilvia Park-
dc.contributor.googleauthorKyoo Hyung Lee-
dc.contributor.googleauthorSoo Jeong Kim-
dc.contributor.googleauthorJung Hee Lee-
dc.contributor.googleauthorDae Young Kim-
dc.contributor.googleauthorSung Soo Yoon-
dc.contributor.googleauthorYeo Keoung Kim-
dc.contributor.googleauthorJun Ho Jang-
dc.contributor.googleauthorSeon Yang Park-
dc.contributor.googleauthorJae Sook Ahn-
dc.contributor.googleauthorChul Won Cheong-
dc.contributor.googleauthorJe Hwan Lee-
dc.contributor.googleauthorJune Won Cheong-
dc.contributor.googleauthorKorean Society of Hematology Acute myeloid Leukemia/Myelodysplastic Syndrome Working Party-
dc.identifier.doi10.1007/s12185-014-1549-3-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00633-
dc.contributor.localIdA00790-
dc.contributor.localIdA03729-
dc.relation.journalcodeJ01120-
dc.identifier.eissn1865-3774-
dc.identifier.pmid24648120-
dc.identifier.urlhttp://link.springer.com/article/10.1007/s12185-014-1549-3-
dc.subject.keywordMyelodysplastic syndrome-
dc.subject.keywordHypomethylating agent-
dc.subject.keywordAlloSCT-
dc.contributor.alternativeNameKim, Soo Jeong-
dc.contributor.alternativeNameKim, Yun Deok-
dc.contributor.alternativeNameCheong, June Won-
dc.contributor.affiliatedAuthorKim, Soo Jeong-
dc.contributor.affiliatedAuthorKim, Yun Deok-
dc.contributor.affiliatedAuthorCheong, June-Won-
dc.rights.accessRightsfree-
dc.citation.volume99-
dc.citation.number5-
dc.citation.startPage635-
dc.citation.endPage643-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF HEMATOLOGY, Vol.99(5) : 635-643, 2014-
dc.identifier.rimsid38461-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.